SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic ...

can be used,” said the DOH supplemental guidance on the use of rapid antigen test kits. Sofia 2 SARS Antigen FIA is the first rapid point-of-care test to be granted emergency use authorization ...

Once the sample is collected by the patient, using a designated self-collection kit ... EUA for a COVID-19 antigen test, developed by Quidel Corporation. The Sofia 2 SARS Antigen FIA test ...

It is the first rapid antigen test for detecting ... capable of performing tests using Sofia 2 instruments. The enhanced Sofia 2 SARS Antigen+ FIA Test kit includes other upgraded features ...

The Sofia® SARS Antigen FIA has not been FDA cleared or approved. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens ...

The Sofia 2 SARS Antigen+ FIA ... The results obtained via the test kit are for the identification of the SARS-CoV-2 nucleocapsid protein antigen, which is generally detectable in upper ...

The Sofia 2 instrument also offers two distinct workflows — WALK AWAY Mode and READ NOW Mode. The results obtained via the test kit are for the identification of the SARS-CoV-2 nucleocapsid protein ...